ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
会议论文

Capivasertib (C) plus fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2e advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort

Hu, X.; Zhang, Q.; Sun, T.; Xiong, H.; Li, W.; Teng, Y.; Lu, Y-S.; Tseng, L-M.; Yan, M.; Li, H.; Pang, D.; Chen, S. C.; Chen, W.; Jiang, O.; Wang, J.; Wu, X.; Fan, E.; Jiang, L.; Zeng, X.; Turner, N.佛山市第一人民医院; 复旦大学; 广州医学院; 华中科技大学; 吉林大学; 哈尔滨医科大学; 郑州大学; 中国医科大学; 1
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)2023-11DOI: 10.1016/j.annonc.2023.10.187
3阅读
引用收藏
分享
相关
加载中…
  • Dalpiciclib plus fulvestrant in HR+/HER2-advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trial
    Zhang, P.; Zhang, Q. Y.; Hu, X.; Li, W.; Tong, Z.; Sun, T.; Teng, Y.; Wu, X.; Ouyang, Q.; Yan, X.; Cheng, J.; Liu, Q.; Feng, J.; Wang, X.; Xu, G.; Wu, F.; Xia, B.; Xu, B.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.被引 1
  • Tolerability and effectiveness of fulvestrant as first-line endocrine therapy in unselected patients with advanced breast cancer (ABC): Results of a multicenter, single arm, non-interventional study
    Zhao, Yannan; Geng, Cuizhi; Zhang, Hongwei; Cai, Li; Yao, Herui; Lin, Ying; Liu, Jianxia; Yang, Jin; Zhang, Jin; Wang, Xiaojia; Li, Yafen; Pang, Danmei; Sun, Tao; Wang, Xi; Ma, Jie; Zang, Aimin; Xu, Zhengyang; Wang, Yongsheng; Wang, Chuan; Hu, XichunAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
  • Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR+/HER2-advanced breast cancer: A phase Ib study.
    Zhang, Qingyuan; Zhang, Pin; Yan, Min; Yan, Xi; Wang, Xian; Gu, Yuanting; Qu, Xiujuan; Li, Shaorong; Xu, Guoying; Yang, Wenhui; Zhu, Xiaoyu; Zhang, Xiaojing; Xu, BingheAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
查看全部 →

会议信息

会议名称
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO)
会议日期
2023-12-01 至 2023-12-03
论文集名
ANNALS OF ONCOLOGY
发表日期
2023-11
起止页码
S1485-S1486
DOI
10.1016/j.annonc.2023.10.187
资助标注
AstraZeneca
收录
ISTP · SCIE

作者

  • H

    Hu, X. (第一作者)

    fudan univ

  • Z

    Zhang, Q.

    harbin med univ

查看全部 20 位作者收起作者
  • S

    Sun, T.

    1 · liaoning canc hosp

  • X

    Xiong, H.

    huazhong univ sci & technol

  • L

    Li, W.

    jilin univ

  • T

    Teng, Y.

    1 · china med univ

  • L

    Lu, Y-S.

  • T

    Tseng, L-M.

  • Y

    Yan, M.

    zhengzhou univ

  • L

    Li, H.

    guangzhou med univ

  • P

    Pang, D.

    first peoples hosp foshan

  • C

    Chen, S. C.

  • C

    Chen, W.

    third hosp nanchang

  • J

    Jiang, O.

  • W

    Wang, J.

  • W

    Wu, X.

    huazhong univ sci & technol · hubei canc hosp

  • F

    Fan, E.

  • J

    Jiang, L.

  • Z

    Zeng, X.

  • T

    Turner, N.

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417